Emergent BioSolutions will Supply additional CYFENDUS anthrax Vaccine doses under a BARDA contract modification valued at $24 million. For investors, the award connects CYFENDUS procurement with U.S. anthrax preparedness efforts and maintains access to a medical countermeasure for post-exposure prophylaxis in eligible adults.
Key Highlights
- CYFENDUS received U.S. Food and Drug Administration approval in July 2023 for post-exposure prophylaxis in people ages 18 through 65.
- Modification No. 21 updates the BARDA AV7909 Contract, which became effective on September 30, 2016.
- An August 2026 statement of work assigns Emergent manufacturing, filling and delivery responsibilities under the contract.
Emergent BioSolutions Inc. (NYSE: EBS) will supply additional CYFENDUS doses under a BARDA contract modification valued at $24 million ($24M), supporting anthrax preparedness efforts. The award covers CYFENDUS, also known as AV7909, an anthrax vaccine procured through the Biomedical Advanced Research and Development Authority. The modification is numbered 21 under the BARDA AV7909 Contract.
$24M CYFENDUS Procurement
Its stated purpose is to procure more doses of CYFENDUS, formally known as Anthrax Vaccine Adsorbed, Adjuvanted. Emergent’s announcement described the contract value as approximately $24 million, while the contract description values the modification at $24 million. The stated rationale is support for anthrax preparedness and continued readiness against anthrax threats.
BARDA Contract Updated
The underlying AV7909 development and procurement agreement became effective on September 30, 2016, and has undergone modifications over time. Modification No. 21 updates the contract’s statement of work and attachment list. The revised statement of work is dated August 2026 and requires Emergent to provide the services, qualified personnel, materials, equipment and facilities needed to carry out the work, except where those resources are supplied by the government. The contract also includes program-management responsibilities covering product-development stages, milestones, timelines and budgets. The work includes emergency-use authorization, licensure, product approval and clearance through the U.S. Food and Drug Administration. It also covers initial product purchase, storage and delivery, along with additional procurement Options and post-marketing requirements.
CYFENDUS Use And Supply
The stated indication covers suspected or confirmed exposure to Bacillus anthracis. The statement of work also assigns manufacturing, filling and delivery of doses procured in fiscal year 2019 for the Strategic National Stockpile.




Please wait processing your request...